The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Dr. Bruce Saffran, fresh from a $500 million court victory and a private settlement with Boston Scientific over a drug-eluting stent patent, is suing Abbott Laboratories (PDF) for violating the same patent with its Xience V stent.
Saffran, a New Jersey radiologist, won the half-billion-dollar verdict against the Natick, Mass.-based devices giant and later settled for an undisclosed amount (although BoSci later posted a $50 million charge on the deal).
Turn your post-op recovery into a fashion statement: With designer Olivier Trillon’s concepts, you can choose between an Yves Saint Laurent or Chanel IV bag for your post-op morphine drip. 
Health Canada approved Abbott’s Xience V drug-eluting stent, which the Chicago-based colossus said it plans to bring to market north of the border immediately.
The device, which competes with Boston Scientific‘s Taxus product, uses a different drug, everolimus, than the paclitaxel-eluting Taxus. The drugs are designed to inhibit the re-growth of vascular tissue around the mesh-like stent.
A pair of studies published in Cardiology Today delivered positive results for Boston Scientific Corp.‘s Taxus and Taxus Express drug-eluting stents.
The first study compared the Taxus paclitaxel-eluting stent with Johnson & Johnson subsidiary Cordis Corp.’s Cypher sirolimus-eluting stent in a total of 6,035 patients. It indicated that, a year after implantation with either device, patients showed “similar rates of clinically important restenosis and ischemic complications.”
Boston Scientific Corp. got a boost from Leerink Swann analyst Rick Wise, who upgraded his rating for the Natick, Mass.-based medical devices giant to “outperform.”
Abbott Vascular extended its post-approval study of the Xience V (PDF) drug-eluting stent, making as many as 2,000 patients in the trial eligible for another study of dual anti-platelet therapy.
The Abbott Park, Ill.-based devices giant said the expansion of the study examining its everolimus-eluting coronary stent opens up the Dual Anti-Platelet Therapy (PDF) trial to more than 2,000 potential subjects.
A federal judge apologized to both parties and the federal bench in overturning a prior, erroneous ruling that a pair of Johnson & Johnson unit Cordis Corp.’s stent patents were unenforceable.
Judge Susan Robinson of the U.S. District Court for the District of Delaware said her 2002 decision in Cordis Corp. v. Boston Scientific Corp. et al. was wrong and reversed the opinion, setting the stage for yet another round in the more than 10-year-old case.
Sales of Boston Scientific Corp.’s Taxus coronary stent remain well off last year’s pace and have declined significantly over the past two years due to increased competition, according to regulatory filings (PDF) by the Vancouver-based pharmaceutical company that makes the drug used in the stent’s coating.
The bad news just keeps on coming for Medtronic Inc., the Minneapolis-based medical device giant.
What a difference a day makes.
Yesterday Boston Scientific Corp. was fielding false claims and Medicare fraud charges.
Today the Natick, Mass.-based medical devices leviathan got word of a possible debt rating upgrade and said the Food & Drug Administration gave pre-market approval to its Taxus Liberté long stent.
Boston Scientific Corp. announced plans for a $128 million research & development lab in Galway, Ireland.
The Natick device maker, which already employs about 5,000 in Ireland, said the project will create roughly 45 jobs over five years, the Independent reported. The lab will focus on early-stage development projects.
